RxDoctor Payments Data

Rakesh Gupta, MD

Internal Medicine · Forest Hills, NYNPI 1366495780

Payments from drug & device makers

$1,938in general payments, 2019–2025

Across 50 payments — averaging $38.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$545
  • Boehringer Ingelheim$437
  • Inari Medical, Inc.$159
  • Dexcom, Inc.$116
  • AbbVie$115
  • Merck$115
  • plus $451 from 11 others

What the payments were for

  • Food & beverage$1,938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,938 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$47,839
Medicare patients
55
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$45,058
JanuviaSitagliptin Phosphate28$26,085
JanumetSitagliptin Phos/Metformin Hcl32$25,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$20,068
OzempicSemaglutide14$15,015
EntrestoSacubitril/Valsartan18$13,583
JardianceEmpagliflozin17$12,737
EliquisApixaban14$12,560
LinzessLinaclotide12$9,907
Spiriva RespimatTiotropium Bromide17$8,800
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,766
Breo ElliptaFluticasone/Vilanterol14$5,279
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,772
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$3,629
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp13$2,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$115$51,56460 claims
AstraZenecaFarxiga$21$45,05843 claims
Boehringer IngelheimJardiance, Spiriva Respimat$437$21,53734 claims
Novo NordiskOzempic$43$15,01514 claims
PfizerEliquis$31$12,56014 claims
AbbVieLinzess$115$9,90712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →